国产精品区一 I 欧美xxxx做受视频 I 亚洲中文字幕人成乱码 I 小早川怜子xxxxaⅴ在线 I 亚洲一区欧美激情 I 黄色免费观看网址 I 91成人小视频 I 日韩在线视频观看 I 强迫大乳人妻中文字幕 I 桃花久久 I 久久天天躁夜夜躁狠狠躁 I 精品人妻伦一二三区久久aaa片 I 日韩亚洲欧美视频 I 欧美国产精品久久久 I 亚洲女人天堂 I 亚洲免费性 I 在线观看国产精品普通话对白精品 I av大秀 I 91av综合 I 两个人看的www视频免费完整版 I 51自拍视频 I 911亚洲精品第一 I 日本美女毛片 I 午夜亚洲福利在线老司机 I 亚洲精品成人av I 亚洲精品无码久久久久av麻豆 I 欧美一级片网站 I 特黄熟妇丰满人妻无码 I 黄色片xxx I 日本熟妇xxxx潮喷视频

Following the NMPA's approval for the marketing application of infliximab biosimilar (CMAB008) on July 14, Kexing Biopharm quickly started working on an overseas sales plan for the drug.

On July 23, a ceremony was held in Taizhou to confirm the first drug registration countries and hand over technical files for commercial cooperation of CMAB008 (infliximab) in the overseas market. The ceremony was held by Kexing Biopharm Co., Ltd. (hereinafter referred to as "Kexing Biopharm", stock code: 688136.SH) and Taizhou Mabtech Pharmaceutical Co., Ltd. (hereinafter referred to as "Taizhou Mabtech"), a wholly-owned subsidiary of Mabpharm Limited (hereinafter referred to as "Mabpharm", stock code: 2181.HK). Kexing Biopharm plans to initiate drug registration in 17 countries, including Brazil, India, Egypt and Indonesia, with some countries expected to start sales in the near future.

The signing ceremony was presided over by Li Yunfeng, ED & CFO of Mabpharm. Other attendees included the following: Wu Xiang, Secretary of Party Working Committee & Director of Management Committee, Jiang Peng, member of Party Working Committee & Deputy Director of Management Committee, Ju Bin, Director of Party and Government Office, Taizhou Medical New & Hi-tech Industrial Development Zone; General Manager Zhao Yanqing and Deputy General Manager Shao Ke of Kexing Biopharm; Wang Hao, Executive Director of Mabpharm; Tao Jing, Executive Director of Mabpharm & General Manager of Taizhou Mabtech.

CMAB008 (infliximab) is mainly used to treat ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis in adults, Crohn's disease, fistulizing Crohn's disease and psoriasis in adults and children over 6 years of age. According to data from Fierce Pharma's website, infliximab saw global sales worth $4,195 million in 2020, ranking top 20 in global drug sales.

CMAB008 (infliximab) was the first infliximab biosimilar drug approved for marketing in China, while also being Taizhou Mabtech's first marketed product. In Taizhou Mabtech search for partners to realize fast drug marketing in the global market, Kexing Biopharm is a perfect fit. Kexing Biopharm has been recognized in the industry in recent years for its business strength and results overseas, as its overseas sales network keeps expanding over the years, thanks to its active involvement in overseas market layout. CMAB008 is another antibody drug in the commercial stage introduced by Kexing Biopharm. With this strong cooperation, Kexing Biopharm can enrich its product pipeline and improve its market layout. Furthermore, thanks to years of international operation experience, Kexing Biopharm has matured and optimized its overseas commercialization, providing strong support to China-made, high-quality biologics for marketing and promotion in foreign countries, helping to serve patients worldwide.